By Kevin E. Noonan — Earlier this month, Eric Sagonowsky reviewed the top ten drugs in the U.S. (in terms of sales) losing patent exclusivity in an article published by Fierce Pharma. These drugs are Lucentis (Genentech/Roche), Bystolic (AbbVie/Allergan), Vascepa (Amarin), Nothera (Lundbeck), Narcan (Emergent Biosolutions), Brovana (Sunovion), Sutent (Pfizer), Saphris (AbbVie/Allergan), Amitiza (Mallinckrodt), and Feraheme (Amag Pharma). The nature of these losses and consequences thereof can be seen from the article, synopsized here. Lucentis (ranibizumab), Roche’s drug for macular degeneration, is a humanized mouse monoclonal antibody fragment specific for vascular endothelial growth factor A. It is related to Roche’s…
